All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study

on behalf of the ALLY-3 Study Team

Research output: Contribution to journalArticlepeer-review

545 Scopus citations

Fingerprint

Dive into the research topics of 'All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study'. Together they form a unique fingerprint.

Medicine and Dentistry

Nursing and Health Professions

Pharmacology, Toxicology and Pharmaceutical Science

Immunology and Microbiology

Neuroscience